ADCT News and Press, ADC Therapeutics SA From 05/06/24

2024-05-06 11:04:07 ET ADC Therapeutics SA (ADCT) Q1 2024 Earnings Conference Call May 06, 2024 08:30 A.M. ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kristen Herrington-Smith - Chief Commercial Offi...

2024-05-06 07:53:53 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy Seeking Alpha’s Quant Rating on ADC Therapeutics Read the full article o...

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares,...

PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....

2024-05-06 06:13:21 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy Seeking Alpha’s Quant Rating on ADC Therapeutics Read the full article o...

ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2...

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ® All patients achieving responses maintained them at the time of data cutoff ...

LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress again...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...